Passage 2: Prokaryotic Cells
Escherichia coli (E. coli) is a gram-negative, rod-shaped bacterium that is
commonly found in the gut of warm-blooded organisms. While most strains of
E. coli are harmless, some can cause serious food poisoning in humans. In recent
years, researchers have been investigating the use of bacteriophages, specifically
the T4 phage, as a potential treatment for antibiotic-resistant E. coli infections.
The T4 phage is a lytic virus that infects E. coli by attaching to specific receptors
on the bacterial cell surface. Once attached, the phage injects its genetic material
into the host cell, hijacking the cell’s machinery to produce new viral components.
The phage then assembles these components into new viral particles, which are
released when the host cell lyses.
To investigate the effectiveness of T4 phage therapy, researchers have conducted
experiments using E. coli-infected mice. They found that a single dose of T4 phage
was able to significantly reduce the bacterial load in the mice’s intestines within
24 hours. Furthermore, the phage treatment did not appear to have any adverse
effects on the mice’s health.
One of the main advantages of using bacteriophages to treat bacterial infections is
their specificity. Unlike broad-spectrum antibiotics, which can kill both harmful and
beneficial bacteria, phages only target specific bacterial strains. This reduces the
risk of developing antibiotic resistance and helps maintain the diversity of the gut
microbiome.
However, there are still challenges to overcome before phage therapy can be widely
implemented. One concern is the potential for bacteria to develop resistance to
phages, similar to how they develop antibiotic resistance. Researchers are also
working on developing methods to ensure that phages remain stable and effective
during storage and delivery.
Despite these challenges, the use of bacteriophages like T4 in treating antibioticresistant E. coli infections shows promise. As research continues, phage therapy may
become an important tool in combating the growing problem of antibiotic resistance.
One of the main advantages of using bacteriophages to treat bacterial
infections is their:
A) Ability to target a wide range of bacterial species
B) Specificity in targeting only specific bacterial strains
C) Rapid mutation rate, allowing them to overcome bacterial resistance
D) Capacity to enhance the immune system’s response to infections
Correct Answer: B
One of the main advantages of using bacteriophages to treat bacterial infections is
their specificity in targeting only specific bacterial strains.
This reduces the risk of developing antibiotic resistance and helps maintain the
diversity of the gut microbiome.